
    
      After the screening period, the patients will be administered 300 IR house dust mite allergen
      based tablets or placebo, once a day, for a period of 36 months with two windows of 8 months
      and 6 months without treatment. The carry over effect will be evaluated after a treatment
      free follow up period of 24 months.

      An independent Data Monitoring Committee will be constituted to evaluate the efficacy and
      safety data at the end of Year 1 and Year 3, and the post-treatment long-term efficacy data
      at the end of year 4.
    
  